title: Chemotherapy and radiotherapy for mesothelioma.
abstract: Previously considered to be rare, malignant pleural mesothelioma (MPM) is a highly aggressive tumor with an increasing incidence linked to asbestos exposure, its main etiological factor. MPM is also a very important issue because patients have usually a short survival (median <12 months) despite current treatments. Moreover an optimal treatment for MPM is not defined yet, even if ERS/ESTS experts recently provided clear and up-to-date guidelines on MPM management. These guidelines on chemotherapy and radiotherapy for mesothelioma, as well as new therapeutic developments, are presented in this chapter.
authors.affiliation: Service de Pneumologie et d'Oncologie Thoracique, Hôpital Calmette, Lille Cedex, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Dhalluin
authors.forename: Arnaud
authors.initials: A
authors.lastname: Scherpereel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001194:Asbestos / Q000633:toxicity; D003131:Combined Modality Therapy; D000077156:Gefitinib; D015316:Genetic Therapy; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008654:Mesothelioma / Q000139:chemically induced / Q000532:radiotherapy / Q000628:therapy*; D010997:Pleural Neoplasms / Q000139:chemically induced / Q000532:radiotherapy / Q000628:therapy*; D011799:Quinazolines / Q000627:therapeutic use; D012260:Ribonucleases / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors; D011799:Quinazolines; D001194:Asbestos; D013792:Thalidomide; D012260:Ribonucleases; D000077156:Gefitinib; C058703:ranpirnase